{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-052289","form_type":"8-K","ticker":"TNGX","cik":"0001819133","company_name":"Tango Therapeutics, Inc.","filed_at":"2023-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.752449+00:00","generated_at":"2026-06-18T22:34:58.935154+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Tango Therapeutics appoints Adam Crystal as President, R&D; base salary $550k, equity grants","bullets":["Adam Crystal, M.D., Ph.D., appointed President, Research & Development, effective Feb 27, 2023.","Annual base salary of $550,000; one-time sign-on bonus of $275,000 (clawback if leaves before Feb 27, 2024).","Equity grants: stock options for 487,500 shares and RSUs for 81,250 shares, with time-based vesting.","Target annual cash incentive of 45% of base salary; severance includes 12 months salary and COBRA coverage.","Crystal previously CMO at C4 Therapeutics and clinical program leader at Novartis."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-052289","json":"https://secwatch.observer/filing/0001193125-23-052289.json","markdown":"https://secwatch.observer/filing/0001193125-23-052289.md","text":"https://secwatch.observer/filing/0001193125-23-052289.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819133/000119312523052289/0001193125-23-052289-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819133/000119312523052289/d297639d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T22:34:58.935154+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5845598f28","claim":"Adam Crystal was appointed as President, Research & Development at Tango Therapeutics, Inc..","evidence_excerpt":"On February 28, 2023, Tango Therapeutics, Inc. (“Tango” or the “Company”) announced that Adam Crystal, M.D., Ph.D., 46 years old, was appointed as the Company’s President, Research & Development, effective as of February 27, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312523052289/0001193125-23-052289-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President, Research & Development"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}